ACLY and breast cancer: Since both lipolytic and lipogenic adaptation mechanisms are present in breast cancer cells, the applied lipid metabolism inhibitors had significant antiproliferative effects only in some cell lines: ETO (a CPT1A/lipid oxidation inhibitor) significantly decreased the cellular growth (by 50%) of T47D cells, whereas BMS (an Acly/lipid synthesis inhibitor) slightly inhibited (~20%) the growth of T47D and HS578T cells (Figure 3).